Obesity and musculoskeletal (MSK) conditions impact a major portion of the American population. With glucagon-like peptide-1 agonists (GLP-1s) rapidly transforming obesity care as well as employer and payer bottom lines, it's more important than ever to consider strategies for sustainable impact. This white paper explores the comorbid nature of obesity and pain and the need for holistic, doctor-led care to navigate the complexities of GLP-1s for long-term gains.
The report has opened in a new window.
If you are interested in learning more about how our doctor-led MSK model can improve outcomes for your members and lower high costs with up to a 4:1 ROI, I would love to connect.
Please schedule a demo or reach out to me directly at teri.jouvenat@vorihealth.com.
I look forward to your reply!
Teri Jouvenat
Senior National Business Development